647 results about "Immunopotency" patented technology

An influenza vaccine adjuvanted with a sub-micron oil-in-water emulsion elicits significantly higher immune responses in human pediatric populations. Compared to an existing unadjuvanted pediatric influenza vaccine, the adjuvanted vaccines provided herein can induce in children a longer persistence of high serum antibody titers and also longer seroconversion and seroprotection. The improvement in immune responses is seen for both influenza A virus and influenza B virus strains, but it is particularly marked for influenza B virus. Moreover, while the existing vaccine provides poor immunity in children after a single dose, the adjuvanted vaccine provides high seroprotection rates against the influenza A virus H3N2 subtype even after a single dose. Furthermore, the adjuvanted vaccine offers significantly better seroprotection against mismatched strains of influenza A virus.

The present invention is based on the discovery of novel species of the genus Helicobacter that are associated with gastro-esophageal ulceration in pigs. In particular, a novel species, H. cerdo, has been used as a source of antigenic material for the development of vaccine for the treatment of the gastro-esophageal disorders. Most advantageously, the novel Helicobacter and the porcine circoviruses associated with PMWS in pigs are useful for providing combination vaccines whereby immunogens derived from both types of pathogens may be codelivered to the target animal to stimulate the generation of protective antibodies and immunity. The invention, therefore, provides vaccines that are useful for the tratment of gastro-esophageal ulceration and PMWS in porcines. The present invention includes, therefore, multivalent immunogenic compositions and vaccines, multivaccine kits, and combined immunization or vaccination methods which make it possible to use such combined immunization or vaccination programmes.

Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

The invention belongs to the field of aquaculture or feed, relates to a aquaculture feed, and especially relates to an alga immunopotentiation compound feed for litopenaeus vannamei. The invention at first provides an immunity strengthening agent for litopenaeus vannamei feed, and the agent is obtained through enzymatic hydrolysis and fermentation of an alga composite. The alga composite is composed of following components in parts by dried weight: 40 to 50 parts of asparagus, 15 to 25 parts of enteromorpha, 10 to 20 parts of ulva lactuca, 5 to 15 parts of laver and 5 to 15 parts of undaria pinnatifida. The invention further prepares a compound feed for litopenaeus vannamei by utilizing the immunity strengthening agent. The alga immunity strengthening agent contains algae polysaccharide, which has the effect of strengthening animal immunity, acrylic acid, terpenes, brominated phenolic and some sulfocompounds, which have the antiseptic effect, and sulphated polysaccharide, which has the antivirus effect. The litopenaeus vannameis fed on the alga immunopotentiation compound feed have a strong anti-stress performance, the body's immunity ability is improved, survival rate is high and culture benefit is remarkable.

Provided are adenoviral vectors for generating an immune response to antigen. The vectors comprise a transcription unit encoding a secretable polypeptide, the polypeptide comprising a secretory signal sequence upstream of a tumor antigen upstream of CD40 ligand, which is missing all or substantially all of the transmembrane domain rendering CD40L secretable. Also provided are methods of generating an immune response against cells expressing a tumor antigen by administering an effective amount of the invention vector. Further provided are methods of generating an immune response against cancer expressing a tumor antigen in an individual by administering an effective amount of the invention vector. Still further provided are methods of generating immunity to infection by human papilloma virus (HPV) by administering an effective amount of the invention vector which enocodes the E6 or E7 protein of HPV. The immunity generated is long term.

The invention discloses a health food for improving immunity and a preparation method thereof. The health food is prepared from the following raw materials in part by weight: 1 to 3 parts of dendrobium officinale, 2 to 6 parts of American ginseng and 6 to 18 parts of Chinese wolfberry. Pharmacological experiments prove that: the health food has an obvious effect of promoting an immune system, canobviously improve a phagocytic index of macrophage of immunosuppressed mice and increase coefficients of immune organs in nonspecifc immune experiments, can improve the conversion rate of lymphocytes, improve the level of immunoglobulin IgG, IgA and IgM in serum of the immunosuppressed mice and assist in conditioning immunodeficiency disease, and diseases such as weakened immune system, low resistance and the like.

The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

Polynucleotides encoding carcinoembryonic antigen (CEA) fusion proteins are provided, the CEA fusion proteins comprising a CEA protein, or functional variant thereof, fused to a substantial portion of an immunoenhancing element. The polynucleotides of the present invention can elicit an immune response in a mammal, which, in preferred embodiments, is stronger than the immune response elicited by a wild-type CEA. The gene encoding CEA is commonly associated with the development of human carcinomas. The present invention provides compositions and methods to elicit or enhance immunity to the protein product expressed by the CEA tumor-associated antigen, wherein aberrant CEA expression is associated with a carcinoma or its development. This invention specifically provides adenoviral vector and plasmid constructs carrying polynucleotides encoding CEA fusion proteins and discloses their use in vaccines and pharmaceutical compositions for preventing and treating cancer.

The invention relates to the field of haemophilus parasuis vaccines in veterinary biological products, in particular to a haemophilus parasuis LC strain. The collection number of the strain is CGMCC (China General Microbiological Culture Collection Center) No.5257. The invention also relates to application of the haemophilus parasuis LC strain to preparation of haemophilus parasuis inactivated vaccines. The haemophilus parasuis LC strain has stronger pathogenicity to pigs and has better immunogenicity; an inactivated alumina gel vaccine prepared by the strain is safe and reliable; not only a homologous attacking protection is provided, but also a better cross protection to blood serums type 4, type 5, type 10, type 12, type 14 and type 15 HPS (Hantavirus Pulmonary Syndrome) heterologous attacking can be provided; after the pigs are immunized, a stronger immunity can be generated and the morbidity and the mortality of the inoculated pigs are obviously reduced; the immune effect achieves or is better than the traditional commercialized vaccines in the market; the vaccine has the advantages to compete with like products at home and abroad and is capable of effectively preventing the epidemic and the transmission of a haemophilus parasuis disease and reducing the economic losses caused by the disease, so that the application range is wide.

The invention relates to the field of a protein and particularly relates to a milk-derived bioactive polypeptide QEPVL with in-vitro antioxidant activity and body immunity promoting activity, wherein an amino acid sequence of the bioactive polypeptide QEPVL is Gln-Glu-Pro-Val-Leu. Through an in-vitro antioxidant test and an in-vitro immunity promoting test, the polypeptide QEPVL is proved to have relatively good antioxidant biological activity and immunity improving function; on one hand, free radicals in the body can be removed to reduce the harm on the human body caused by the free radicals; on the other hand, according to the bioactive polypeptide QEPVL, the immunity of the body can be further enhanced and the multiplication capacity of lymphocytes in vitro can be promoted, thereby improving the ability of the body to resist infections of external pathogens and reducing the incidence rate of the body without causing immunological rejections. The bioactive polypeptide QEPVL has great significance for the development of milk products, healthcare products and medicines with the antioxidant function and the immunity enhancement.

The invention discloses a method and a device for evaluating an immunity level. The method comprises the steps of separating lymphocyte from a testee sample, extracting the RNA of the lymphocyte and performing reverse transcription, obtaining a BCR and / or TCR variable region polynucleotides by means of a specific primer, performing sequencing on the polynucleotides for obtaining sequence information, and calculating the D50 value of a BCR and / or TCR variable region sequence, thereby determining the immunity level of the testee.